Wyeth 

(Public, NYSE:WYE-)   Watch this stock   
Find more results for WYE

Key stats and ratios

Q2 (Jun '09) 2008
Net profit margin 22.34% 19.35%
Operating margin 31.72% 27.76%
EBITD margin - 32.28%
Return on average assets 11.39% 10.19%
Return on average equity 25.19% 23.63%
Employees 47,426 -

Address

Five Giralda Farms
Madison, NJ 07940
United States - Map
+1-973-6605000 (Phone)
+1-973-6605771 (Fax)

Website links

Wyeth discussions

Wyeth and Merck May See Increased Orders for their Pneumonia Vaccines this Flu Season
Public Health - Oct 9, 2009   (1 post)
A significant amount of the hospitalizations and deaths associated with an initial influenza infections are due to secondary pneumonias that develop during the course or an individual attempting to fight the flu. One way to protect ...
Timeline for the merger
audi..@gmail.com - Jun 8, 2009   (1 post)
Does anybody know where one can get updates on the merger?
Re: Wyeth, buy or sell??
eric...@gmail.com - May 21, 2009   (12 posts)
WYE is a good buy if its below 47, but its an amazing buy at any price below 44.45. It is straight up risk arbitrage with a 30 cent quarterly dividend. That's 1.20 annualized dividend, at 44.00 its a more than 2% return only counting ...

Description

Wyeth is engaged in the discovery, development, manufacture, distribution and sale of a line of products in three primary businesses: Wyeth Pharmaceuticals (Pharmaceuticals), Wyeth Consumer Healthcare (Consumer Healthcare), and Fort Dodge Animal Health (Animal Health). Pharmaceuticals include branded human ethical pharmaceuticals, biotechnology products, vaccines and nutrition products. Pharmaceuticals products include neuroscience therapies, musculoskeletal therapies, vaccines, nutritional products, anti-infectives, women’s healthcare products, hemophilia treatments, gastroenterology drugs, immunological products and oncology therapies. Consumer Healthcare products include pain management therapies, including analgesics and heat wraps, cough/cold/allergy remedies, nutritional supplements, and hemorrhoidal care and personal care items sold over-the-counter (OTC). In October 2009, Pfizer Inc. acquired Wyeth.

Officers and directors

Bernard J. Poussot
Chairman of the Board, President, Chief Executive Officer
Age: 57
Gregory Norden
Chief Financial Officer, Senior Vice President
Age: 51
Richard R. DeLuca Jr.
President - Fort Dodge Animal Health
Age: 46
Cavan M. Redmond
President - Wyeth Consumer Healthcare
Age: 48
Geno J. Germano
President - U.S., Pharmaceuticals and Women’s Health Care - Wyeth Pharmaceuticals
Age: 48
Andreas Krebs
President, Europe, Middle East, Africa (EMEA) and Canada
Age: 51
Michael E. Kamarck Ph.D.
President - Technical Operations & Product Supply (TO&PS)
Age: 57
Charles A. Portwood
EVP - Technical Operations and Product Supply Operational Excellence - Wyeth Pharmaceuticals
Age: 58
Lawrence V. Stein
Senior Vice President, General Counsel
Age: 59
Denise M. Peppard
Senior Vice President - Human Resources
Age: 52